Skip to content
2000
image of Comparative Effectiveness of Daily Oral and Long-acting Injectable Prep: A Critical Review of Clinical Evidence and Public Health Implications

Abstract

The Human Immunodeficiency Virus (HIV) is the cause of Acquired Immunodeficiency Syndrome (AIDS). Preexposure Prophylaxis (PrEP) antiretroviral drugs to prevent HIV-1 infection are currently available in many countries. In Brazil, the recommended and approved regimen for PrEP is a daily Fixed-Dose Combination (FDC) tablet of Tenofovir Disoproxil Fumarate (TDF) with Emtricitabine (FTC) (300/200 mg), marketed as Truvada®. However, adherence to daily oral pill regimens remains one of the greatest challenges for the successful use of PrEP. Therefore, a Long-Acting Injectable (LAI) PrEP regimen, such as Cabotegravir (CAB), could significantly improve adherence to prophylaxis. The aim of this study was to compare the use of PrEP with TDF+FTC and the long-acting injectable cabotegravir, as well as to examine the mechanisms of action of the drugs involved in PrEP. In fact, the results confirmed the safety and efficacy of the use of CAB as an LAI PrEP. In June 2025, the FDA approved the use of LEN for PrEP, and it is expected that other regulatory agencies will follow suit by the end of the year. Emerging strategies under development include annual LEN formulations, the use of broadly Neutralizing Antibodies (bNAbs), and the Dapivirine Vaginal Ring (DPV), which has demonstrated greater convenience and improved adherence among pregnant women compared to oral PrEP. Additionally, digital monitoring tools are being explored, although their effectiveness relies on the implementation of equitable health policies. Thus, integrated prevention models that combine biomedical innovations with community-based interventions emerge as essential to expanding the reach and impact of PrEP.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X426548251031113228
2026-01-23
2026-01-29

  • From This Site

    /content/journals/chr/10.2174/011570162X426548251031113228
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Vaishnav Y.N. Wong-Staal F. The biochemistry of AIDS. Annu. Rev. Biochem. 1991 60 1 577 630 10.1146/annurev.bi.60.070191.003045 1883204
    [Google Scholar]
  2. Estatísticas 2025 UNAIDS. Available from: https://unaids.org.br/estatisticas/#:~:text=630%20mil%20%5B480%20mil%20%E2%80%%93%20880,desde%20o%20in%C3%ADcio%20da%20epidemia
  3. Ullah Nayan M. Sillman B. Hasan M. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Adv. Drug Deliv. Rev. 2023 200 115009 10.1016/j.addr.2023.115009 37451501
    [Google Scholar]
  4. Grant R.M. Lama J.R. Anderson P.L. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010 363 27 2587 2599 10.1056/NEJMoa1011205 21091279
    [Google Scholar]
  5. Grant R.M. Mannheimer S. Hughes J.P. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: The human immunodeficiency virus prevention trials network 067/ADAPT study. Clin. Infect. Dis. 2018 66 11 1712 1721 10.1093/cid/cix1086 29420695
    [Google Scholar]
  6. Moss J.A. Srinivasan P. Smith T.J. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob. Agents Chemother. 2014 58 9 5125 5135 10.1128/AAC.02871‑14 24936594
    [Google Scholar]
  7. Schaefer R. Schmidt H.M.A. Ravasi G. Adoption of guidelines on and use of oral pre-exposure prophylaxis: A global summary and forecasting study. Lancet HIV 2021 8 8 e502 e510 10.1016/S2352‑3018(21)00127‑2 34265283
    [Google Scholar]
  8. Brizzi M. Sherman E.M. Green S.B. Personalizing prevention: Advances in pharmacotherapy for HIV prevention. Pharmacotherapy 2023 43 4 305 320 10.1002/phar.2796 36938645
    [Google Scholar]
  9. Zucchi E.M. Grangeiro A. Ferraz D. Da evidência à ação: De-safios do Sistema Único de Saúde para ofertar a profilaxia pré-ex-posição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade. [From evidence to action: challenges faced by the Unified Health System to offer HIV pre-exposure prophylaxis (PrEP) to people at highest vulnerability] Cad. Saude Publica 2018 34 7 e00206617
    [Google Scholar]
  10. Baeten J.M. Donnell D. Mugo N.R. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: An update of data from a randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 2014 14 11 1055 1064 10.1016/S1473‑3099(14)70937‑5 25300863
    [Google Scholar]
  11. Molina J-M. Capitant C. Spire B. On Demand PrEP With oral TDF-FTC in MSM: Results of the ANRS ipergay trial. Conference on retroviruses and opportunistic infections. Seattle, Washington Feburary 23-26, 2015.
    [Google Scholar]
  12. Chen X. Seifert S.M. Castillo-Mancilla J.R. Model linking plasma and intracellular tenofovir/emtricitabine with deoxynucleoside triphosphates. PLoS One 2016 11 11 e0165505 10.1371/journal.pone.0165505 27832147
    [Google Scholar]
  13. Koss C.A. Bacchetti P. Hillier S.L. Differences in cumulative exposure and adherence to tenofovir in the VOICE, iPrEx OLE, and PrEP demo studies as determined via hair concentrations. AIDS Res. Hum. Retroviruses 2017 33 8 778 783 10.1089/aid.2016.0202 28253024
    [Google Scholar]
  14. Noret M. Balavoine S. Pintado C. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. AIDS 2018 32 15 2161 2169 10.1097/QAD.0000000000001939 30212403
    [Google Scholar]
  15. Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV 2024 Ontario HIV Treatment Network. Available from: https://www.ohtn.on.ca/rapid-response-effectiveness-of-oral-pre-exposure-prophylaxis-prep-for-hiv/
  16. Milam J. Jain S. Dubé M.P. Sexual risk compensation in a pre-exposure prophylaxis demonstration study among individuals at risk of HIV. J. Acquir. Immune Defic. Syndr. 2019 80 1 e9 e13 10.1097/QAI.0000000000001885 30334877
    [Google Scholar]
  17. Marrazzo J.M. Ramjee G. Richardson B.A. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 2015 372 6 509 518 10.1056/NEJMoa1402269 25651245
    [Google Scholar]
  18. van der Straten A. Van Damme L. Haberer J.E. Bangsberg D.R. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012 26 7 F13 F19 10.1097/QAD.0b013e3283522272 22333749
    [Google Scholar]
  19. Tetteh R.A. Yankey B.A. Nartey E.T. Lartey M. Leufkens H.G.M. Dodoo A.N.O. Pre-exposure prophylaxis for HIV prevention: Safety concerns. Drug Saf. 2017 40 4 273 283 10.1007/s40264‑017‑0505‑6 28130774
    [Google Scholar]
  20. Cohen M.S. Baden L.R. Preexposure prophylaxis for HIV-Where do we go from here? N. Engl. J. Med. 2012 367 5 459 461 10.1056/NEJMe1207438 22784041
    [Google Scholar]
  21. Baeten J.M. Donnell D. Ndase P. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 2012 367 5 399 410 10.1056/NEJMoa1108524 22784037
    [Google Scholar]
  22. Paltiel A.D. Freedberg K.A. Scott C.A. HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin. Infect. Dis. 2009 48 6 806 815 10.1086/597095 19193111
    [Google Scholar]
  23. Kibengo F.M. Ruzagira E. Katende D. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One 2013 8 9 e74314 10.1371/journal.pone.0074314 24086333
    [Google Scholar]
  24. Choopanya K. Martin M. Suntharasamai P. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013 381 9883 2083 2090 10.1016/S0140‑6736(13)61127‑7 23769234
    [Google Scholar]
  25. McCormack S. Dunn D.T. Desai M. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016 387 10013 53 60 10.1016/S0140‑6736(15)00056‑2 26364263
    [Google Scholar]
  26. Markowitz M. Frank I. Grant R.M. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): A multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 2017 4 8 e331 e340 10.1016/S2352‑3018(17)30068‑1 28546090
    [Google Scholar]
  27. Landovitz R.J. Li S. Grinsztejn B. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 15 11 e1002690 10.1371/journal.pmed.1002690 30408115
    [Google Scholar]
  28. Murray M.I. Markowitz M. Frank I. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clin. Trials 2018 19 4 129 138 10.1080/15284336.2018.1511346 30445896
    [Google Scholar]
  29. Tolley E.E. Zangeneh S.Z. Chau G. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020 24 9 2520 2531 10.1007/s10461‑020‑02808‑2 32052214
    [Google Scholar]
  30. HPTN 077 2017 HIV Prevention Trials Network. Available from: https://www.hptn.org/research/studies/hptn077
  31. Canetti D. Spagnuolo V. An evaluation of cabotegravir for HIV treatment and prevention. Expert Opin. Pharmacother. 2021 22 4 403 414 10.1080/14656566.2020.1843635 33112699
    [Google Scholar]
  32. Han K. Wannamaker P. Lu H. Safety, tolerability, pharmacokinetics, and acceptability of oral and long-acting cabotegravir in HIV-negative Chinese men. Antimicrob. Agents Chemother. 2022 66 3 e02057 e21 10.1128/aac.02057‑21 35129374
    [Google Scholar]
  33. HPTN 083 2024 HIV Prevention Trials Network. Available from: https://www.hptn.org/research/studies/hptn083
  34. Landovitz R.J. Donnell D. Clement M.E. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 2021 385 7 595 608 10.1056/NEJMoa2101016 34379922
    [Google Scholar]
  35. HPTN 083-01 2025 HIV Prevention Trials Network. Available from: https://www.hptn.org/research/studies/083-01
  36. Durham (NC): HIV prevention trials network. 2020 HIV Prevention Trials Network. Available from: https://www.hptn.org/news-and-events/announcements/hptn-launches-hptn-083-01
  37. Apretude: EPAR – Public assessment report 2023 European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/assessment-report/apretude-epar-public-assessment-report_en.pdf
  38. HPTN084 2020 HIV Prevention Trials Network. Available from: https://www.hptn.org/research/studies/hptn084
    [Google Scholar]
  39. Jamieson L. Johnson L.F. Nichols B.E. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: A modelled economic evaluation and threshold analysis. Lancet HIV 2022 9 12 e857 e867 10.1016/S2352‑3018(22)00251‑X 36356603
    [Google Scholar]
  40. Neilan A.M. Landovitz R.J. Le M.H. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States. Ann. Intern. Med. 2022 175 4 479 489 10.7326/M21‑1548 35099992
    [Google Scholar]
  41. Cairns G. To be cost effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP 2021 Available from: https://www.aidsmap.com/news/mar-2021/be-cost-effective-injectable-prep-can-only-cost-about-3000-more-us-generic-oral-prep
  42. Paranhos J. Castilho M. Klein H.E. Custos de implementação do cabotegravir injetável de longa duração como profilaxia ao HIV no Brasil. [Implementation costs of long-acting injectable cabotegravir as HIV prophylaxis in Brazil] Physis 2023 33 e33021 10.1590/s0103‑7331202333021
    [Google Scholar]
  43. Anvisa approves a new medicine for HIV prophylaxis 2023 National Health Surveillance Agency (Anvisa). Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2023/anvisa-aprovou-um-novo-medicamento-para-a-profilaxia-do-hiv
  44. Foka F.E.T. Mufhandu H.T. Current ARTs, virologic failure, and implications for AIDS management: A systematic review. Viruses 2023 15 8 1732 10.3390/v15081732 37632074
    [Google Scholar]
  45. Amblard F. Patel D. Michailidis E. HIV nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem. 2022 240 114554 10.1016/j.ejmech.2022.114554 35792384
    [Google Scholar]
  46. Fernandes L.R. Lopes J.R. Bonjorno A.F. Prates J.L.B. Scarim C.B. Dos Santos J.L. The application of prodrugs as a tool to enhance the properties of nucleoside reverse transcriptase inhibitors. Viruses 2023 15 11 2234 10.3390/v15112234 38005911
    [Google Scholar]
  47. Bianco M.C.A.D. Inacio Leite D. Silva Castelo Branco F. The Use of Zidovudine pharmacophore in multi-target-directed ligands for AIDS therapy. Molecules 2022 27 23 8502 10.3390/molecules27238502 36500608
    [Google Scholar]
  48. Gibson A.K. Shah B.M. Nambiar P.H. Schafer J.J. Tenofovir Alafenamide. Ann. Pharmacother. 2016 50 11 942 952 10.1177/1060028016660812 27465879
    [Google Scholar]
  49. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem. Pharmacol. 2016 119 1 7 10.1016/j.bcp.2016.04.015 27133890
    [Google Scholar]
  50. Lee W.A. Martin J.C. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res. 2006 71 2-3 254 259 10.1016/j.antiviral.2006.05.020 16837073
    [Google Scholar]
  51. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochem. Pharmacol. 2011 82 2 99 109 10.1016/j.bcp.2011.03.027 21501598
    [Google Scholar]
  52. Starosotnikov A.M. Bastrakov M.A. Recent developments in the synthesis of HIV-1 integrase strand transfer inhibitors incorporating pyridine moiety. Int. J. Mol. Sci. 2023 24 11 9314 10.3390/ijms24119314 37298265
    [Google Scholar]
  53. Sayyed S.K. Quraishi M. Jobby R. A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants. Arch. Microbiol. 2023 205 4 142 10.1007/s00203‑023‑03461‑8 36966200
    [Google Scholar]
  54. Chou R. Evans C. Hoverman A. Preexposure prophylaxis for the prevention of HIV infection. JAMA 2019 321 22 2214 2230 10.1001/jama.2019.2591 31184746
    [Google Scholar]
  55. Calabrese S.K. Krakower D.S. Mayer K.H. Integrating HIV Preexposure Prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities. Am. J. Public Health 2017 107 12 1883 1889 10.2105/AJPH.2017.304061 29048955
    [Google Scholar]
  56. Logie C.H. Williams C.C. Wang Y. Adapting stigma mechanism frameworks to explore complex pathways between intersectional stigma and HIV-related health outcomes among women living with HIV in Canada. Soc. Sci. Med. 2019 232 129 138 10.1016/j.socscimed.2019.04.044 31079013
    [Google Scholar]
  57. Linley L. Prejean J. An Q. Chen M. Hall H.I. Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005-2008. Am. J. Public Health 2012 102 8 1527 1534 10.2105/AJPH.2011.300431 22698035
    [Google Scholar]
  58. Poteat T. Malik M. Scheim A. Elliott A. HIV prevention among transgender populations: Knowledge gaps and evidence for action. Curr. HIV/AIDS Rep. 2017 14 4 141 152 10.1007/s11904‑017‑0360‑1 28752285
    [Google Scholar]
  59. Grace D. Jollimore J. MacPherson P. Strang M.J.P. Tan D.H.S. The pre-exposure prophylaxis-stigma paradox: Learning from Canada’s first wave of PrEP users. AIDS Patient Care STDS 2018 32 1 24 30 10.1089/apc.2017.0153 29185801
    [Google Scholar]
  60. Choko A.T. Kumwenda M.K. Johnson C.C. Acceptability of woman‐delivered HIV self‐testing to the male partner, and additional interventions: A qualitative study of antenatal care participants in Malawi. J. Int. AIDS Soc. 2017 20 1 21610 10.7448/IAS.20.1.21610 28691442
    [Google Scholar]
  61. Massud I. Krovi A. Nishiura K. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. J. Antimicrob. Chemother. 2022 77 11 2964 2971 10.1093/jac/dkac252 35913838
    [Google Scholar]
  62. Gunawardana M. Remedios-Chan M. Miller C.S. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother. 2015 59 7 3913 3919 10.1128/AAC.00656‑15 25896688
    [Google Scholar]
  63. Li L. Johnson L.M. Krovi S.A. Demkovich Z.R. van der Straten A. Performance and stability of tenofovir alafenamide formulations within subcutaneous biodegradable implants for HIV pre-exposure prophylaxis (PrEP). Pharmaceutics 2020 12 11 1057 10.3390/pharmaceutics12111057 33167509
    [Google Scholar]
  64. Kinsale T.S. Cottrell M.L. Li L. Pharmacokinetic modeling to guide preclinical development of an islatravir-eluting reservoir-style biodegradable implant for long-acting HIV PrEP. Pharmaceutics 2024 16 2 201 10.3390/pharmaceutics16020201 38399255
    [Google Scholar]
  65. Johnson J.E. Brotherton A.L. Rossi M.R. Sanchez M.C. Beckwith C.G. Long-acting injectable antiretroviral therapy for treatment of human immunodeficiency virus: A review. Curr. HIV/AIDS Rep. 2025 22 1 31 10.1007/s11904‑025‑00741‑4 40266468
    [Google Scholar]
  66. McKellar M.S. Lenacapavir: A first-in-class capsid inhibitor for HIV treatment and prevention. Curr. Opin. Infect. Dis. 2025 38 3 208 213 10.1097/QCO.0000000000001113 40276818
    [Google Scholar]
  67. Gilead Sciences, Inc. Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) (PURPOSE 3). NCT06101329. 2025 Available from: https://clinicaltrials.gov/study/NCT06101329
    [Google Scholar]
  68. Gilead Sciences, Inc. PURPOSE 4: A phase 2, open-label, randomized study to evaluate the pharmacokinetics and safety of subcutaneous lenacapavir compared to daily oral FTC/TDF in people who inject drugs. NCT06101342. 2025 Available from: https://clinicaltrials.gov/study/NCT06101342
    [Google Scholar]
  69. Gilead Sciences, Inc. PURPOSE 1: A phase 3, double-blind, randomized study to evaluate the efficacy of subcutaneous lenacapavir compared to daily oral FTC/TAF for HIV pre-exposure prophylaxis in HIV-negative adolescent and young cisgender women. NCT04994509. 2025 Available from: https://clinicaltrials.gov/study/NCT04994509
    [Google Scholar]
  70. Gilead Sciences, Inc. PURPOSE 2: A phase 3, double-blind, multicenter, randomized study to evaluate the efficacy and safety of subcutaneous twice-yearly lenacapavir for HIV pre-exposure prophylaxis in cisgender men, transgender women, transgender men, and gender nonbinary people ≥16 years of age who have sex with male partners and are at risk for HIV infection. NCT04925752. 2024 Available from: https://clinicaltrials.gov/study/NCT04925752
    [Google Scholar]
  71. Gilead Sciences, Inc. PURPOSE 5: A phase 2 clinical trial to evaluate the persistence of subcutaneous lenacapavir compared to daily oral FTC/TDF for HIV Pre-Exposure Prophylaxis in France and the United Kingdom. NCT06101329. 2025 Available from: https://clinicaltrials.gov/study/NCT06101329
    [Google Scholar]
  72. Neverette N.C. Dumond J.B. McMahon D.K. Devanathan A.S. Lenacapavir: Playing the long game in the new era of antiretrovirals. Clin. Pharmacol. Ther. 2025 117 2 353 367 10.1002/cpt.3447 39323028
    [Google Scholar]
  73. Matthews R.P. Patel M. Barrett S.E. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: A randomized, placebo-controlled phase 1 trial. Nat. Med. 2021 27 10 1712 1717 10.1038/s41591‑021‑01479‑3 34608329
    [Google Scholar]
  74. Jogiraju V. Pawar P. Yager J. Pharmacokinetics and safety of once-yearly lenacapavir: A phase 1, open-label study. Lancet 2025 405 10485 1147 1154 10.1016/S0140‑6736(25)00405‑2 40086460
    [Google Scholar]
  75. Caskey M. Klein F. Lorenzi J.C.C. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015 522 7557 487 491 10.1038/nature14411 25855300
    [Google Scholar]
  76. Barouch D.H. Whitney J.B. Moldt B. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013 503 7475 224 228 10.1038/nature12744 24172905
    [Google Scholar]
  77. Baeten J.M. Palanee-Phillips T. Brown E.R. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 2016 375 22 2121 2132 10.1056/NEJMoa1506110 26900902
    [Google Scholar]
  78. Nel A. van Niekerk N. Kapiga S. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N. Engl. J. Med. 2016 375 22 2133 2143 10.1056/NEJMoa1602046 27959766
    [Google Scholar]
  79. Montgomery E.T. van der Straten A. Chitukuta M. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS 2017 31 8 1159 1167 10.1097/QAD.0000000000001452 28441175
    [Google Scholar]
  80. Montgomery E.T. Hawley I. Fairlie L. Acceptability of the dapivirine vaginal ring and oral truvada among African users in late-stage of pregnancy. AIDS Behav. 2024 28 3 963 973 10.1007/s10461‑023‑04203‑z 37932492
    [Google Scholar]
  81. Brisson J. Castro-Arteaga M. Apedaile D. Perez-Brumer A. Enhancing daily oral PrEP adherence with digital communications: Protocol for a systematic review and meta-analysis. PLoS One 2024 19 11 e0313322 10.1371/journal.pone.0313322 39531430
    [Google Scholar]
  82. Haines M. Vandyk A. Skidmore B. Orser L. O’Byrne P. A systematic review of oral pre-exposure prophylaxis HIV adherence interventions. J. Assoc. Nurses AIDS Care 2024 35 4 309 324 10.1097/JNC.0000000000000460 38564213
    [Google Scholar]
  83. Sidebottom D. Ekström A.M. Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV – How can we improve uptake and adherence? BMC Infect. Dis. 2018 18 1 581 10.1186/s12879‑018‑3463‑4 30445925
    [Google Scholar]
  84. Brown B.J. Sugarman J. Why ethics guidance needs to be updated for contemporary HIV prevention research. J. Int. AIDS Soc. 2020 23 5 e25500 10.1002/jia2.25500 32406990
    [Google Scholar]
/content/journals/chr/10.2174/011570162X426548251031113228
Loading
Comparative Effectiveness of Daily Oral and Long-acting Injectable Prep: A Critical Review of Clinical Evidence and Public Health Implications
Bentham Science Publishers ; https://doi.org/10.2174/011570162X426548251031113228
/content/journals/chr/10.2174/011570162X426548251031113228
/content/journals/chr/10.2174/011570162X426548251031113228
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: long-acting injectable ; fixed-dose combination ; cabotegravir ; tenofovir ; PrEP ; emtricitabine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test